Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through ... success of ...

A new study found that many people on Medicare with low to moderate incomes don't have enough money to pay for a hospital ...

Bottom line, if you’re an average working person out there do you really think that the Democratic Party is going to the mat, taking on powerful special interests, and fighting for you? I ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Hello, and thank you for standing by. My name is Regina, and I ...

Everyone's got a favorite root beer, but which one is truly the best of the best? We tasted a bunch of popular root beer ...

One of the key reasons is the encouraging discussions with the FDA, indicating that the regulatory body has ... based on its potential to generate real-world cost savings, highlights an optimistic ...

The investigation is in its early stages, and 33 patients have been discovered. The Food and Drug Administration has not released any patient information, such as where the patients live or their ...

NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics ...

Analysis time of SR-DLS is considerably shorter compared to conventional DLS. A SR-DLS measurement takes less than 10 seconds ...